Friday, July 10, 2026

Drug profile · INN

allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)

allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2) (ZALMOXIS) is a somatic cell supplemental therapy.

EMA: withdrawn Antineoplastic and immunomodulating agents (L01) L01
Patents linked 0
Pipeline programs 30
News articles 0
Drug details — allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Class
Antineoplastic and immunomodulating agents (L01)
Route
Patents
0
Programs
30
Data quality
0.83

Quick answer

allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2) (ZALMOXIS) is a somatic cell supplemental therapy.

Key facts

INN allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Brand ZALMOXIS
Mechanism Somatic cell supplemental therapy
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01

Mechanism of action

Somatic cell supplemental therapy

Approval history

Authority Status Date
EMA withdrawn

Pipeline programs

  1. 090701 Phase 3 · Baxalta Innovations · Hemophilia A or B With Inhibitors
  2. 090701 Phase 3 · Takeda · Hemophilia A or B With Inhibitors
  3. Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)] Phase 3 · Teva Pharma · Healthy
  4. acyclovir Phase 3 · Ultragenyx UK · Herpes Simplex
  5. 2G-MSC-GVHD Phase 2 · George Institute for · Patients who have developed acute GVHD refractory to cortico
  6. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS Phase 2 · Lxo Ireland Designated · Sars-CoV2
  7. Allogeneic Cardiosphere-Derived Cells (CAP-1002) Phase 2 · CAPRICOR THERAPEUTICS · Duchenne Muscular Dystrophy
  8. Allogeneic MSC (AlloMSC) Phase 2 · Chinese Academy of · Refractory Systemic Lupus Erythematosus

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)?

allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2) (ZALMOXIS) is a somatic cell supplemental therapy.

What is the brand name for allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)?

ZALMOXIS is a marketed brand name for allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2). Check FDA Drugs@FDA for the current US label holder and prescribing information.